ReviewFrontiers in pharmacology2025
Recent advances in the role of polysaccharides in liver diseases: a review.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Physicochemical Characterization and In Vitro Hypoglycemic Activity of a Low-Molecular-Weight Extracellular Polysaccharide From Deep-Sea Beauveria bassiana.Chemistry & biodiversity · 2026Article
- Adipose Tissue Aging and Natural Interventions: Potential Roles of Polyphenols and Polysaccharides.Nutrients · 2026Review
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver diseases are a serious health problem worldwide, especially with a sustained increase in the burden of it every year. However, drugs commonly used in patients have limited efficacy and serious adverse reactions associated with long-term use. Therefore, it is urgent to find effective and safe alternatives. Polysaccharides are currently considered promising alternatives to traditional drugs because of their extensive activity and low toxicity. This review investigated the studies on hepatoprotective polysaccharides over the past 6 years, detailing their hepatoprotective effects, potential mechanisms, and drug carrier applications. These findings suggest that polysaccharides have prominent preventive and therapeutic effects on various liver diseases such as drug-induced liver injury, alcoholic liver disease, hepatitis B, non-alcoholic fatty liver disease, liver fibrosis, and hepatocellular carcinoma. Its mechanism includes multiple aspects such as metabolic regulation, reduction of oxidative stress and inflammation, and regulation of gut microbiota. Furthermore, owing to the good physicochemical properties, polysaccharides have been applied in delivery systems for chemotherapy drugs and small molecule drugs. However, further research is essential on the bioavailability, structure-activity relationship, and more clinical evidence of polysaccharides. Continued exploration of polysaccharides will provide tremendous potential for the treatment of liver diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.